COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,886 Articles (22,568 medRxiv, 8,318 bioRxiv)

Most recent first Previous |  Page 3056: Articles 30551-30560  | Next

Strategies for vaccine design for corona virus using Immunoinformatics techniques
Basu, A., Sarkar, A., Maulik, U.
10.1101/2020.02.27.967422 — Posted: 2020-03-02
Predictions for the binding domain and potential new drug targets of 2019-nCoV
Zeng, Z., Zhi, L., Du, H.
10.1101/2020.02.26.961938 — Posted: 2020-03-02
The within-host viral kinetics of SARS-CoV-2
Li, C., Jinhu, X., Liu, J., Zhou, Y.
10.1101/2020.02.29.965418 — Posted: 2020-03-02
Molecular Dynamics Simulations Indicate the COVID-19 Mpro Is Not a Viable Target for Small-Molecule Inhibitors Design
Bzowka, M., Mitusinska, K., Raczynska, A., Samol, A., Tuszynski, J. A., Gora, A.
10.1101/2020.02.27.968008 — Posted: 2020-03-02
Kallikrein 13: a new player in coronaviral infections.
Milewska, A., Falkowski, K., Kalinska, M., Bielecka, E., Naskalska, A., Mak, P., Lesner, A., Ochman, M., Urlik, M., Potempa, J., Kantyka, T., Pyrc, K.
10.1101/2020.03.01.971499 — Posted: 2020-03-02
Comparative genomic analysis revealed specific mutation pattern between human coronavirus SARS-CoV-2 and Bat-SARSr-CoV RaTG13
Lv, L., Li, G., Chen, J., Liang, X., Li, Y.
10.1101/2020.02.27.969006 — Posted: 2020-03-02 Discussion: Onsite
TWIRLS, an automated topic-wise inference method based on massive literature, suggests a possible mechanism via ACE2 for the pathological changes in the human host after coronavirus infection
Ji, X., Zhang, C., Zhai, Y., Zhang, Z., Zhang, C., Xue, Y., Tan, G., Niu, G.
10.1101/2020.02.27.967588 — Posted: 2020-03-02 Discussion: Offsite
Mutations, Recombination and Insertion in the Evolution of 2019-nCoV
Wu, A., Niu, P., Wang, L., Zhou, H., Zhao, X., Wang, W., Wang, J., Ji, C., Ding, X., Wang, X., Lu, R., Gold, S., Aliyari, S., Zhang, S., Vikram, E., Zou, A., Lenh, E., Chen, J., Ye, F., Han, N., Peng, Y., Guo, H., Wu, G., Jiang, T., Tan, W., Cheng, G.
10.1101/2020.02.29.971101 — Posted: 2020-03-02 Discussion: Onsite
Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches
Tahir ul Qamar, M., Rehman, A., Ashfaq, U. A., Awan, M. Q., Fatima, I., Shahid, F., Chen, L.-L.
10.1101/2020.02.28.970343 — Posted: 2020-03-02 Discussion: Onsite
CRISPR-based COVID-19 surveillance using a genomically-comprehensive machine learning approach
Metsky, H. C., Freije, C. A., Kosoko-Thoroddsen, T.-S. F., Sabeti, P. C., Myhrvold, C.
10.1101/2020.02.26.967026 — Posted: 2020-03-02

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).